MERCK SHARP & DOHME CORP. v MERCK KGaA

Case Details

• Citation: [2021] SGCA 14
• Court: Court of Appeal of the Republic of Singapore
• Date of Decision: 26 February 2021
• Case Title: Merck Sharp & Dohme Corp v Merck KGaA
• Civil Appeal No: 223 of 2019
• Related Suit: Suit No 415 of 2018 (Summons No 4434 of 2018)
• Judges: Sundaresh Menon CJ; Andrew Phang Boon Leong JCA; Judith Prakash JCA; Steven Chong JCA; Quentin Loh JAD
• Plaintiff/Applicant: Merck Sharp & Dohme Corp (formerly known as Merck & Co, Inc)
• Defendant/Respondent: Merck KGaA (formerly known as E Merck)
• Procedural Posture (as reflected in the extract): Appeal from the High Court in proceedings involving an application for summary judgment and related defences including abuse of process and issue estoppel
• Core Doctrines Discussed: Abuse of process; Henderson v Henderson doctrine; issue estoppel; cause of action estoppel; transnational issue estoppel (foreign judgment)
• Key Background Dispute: Co-existence agreement governing use of the name “Merck” (1970 Agreement and 1975 Letter)
• Relevant Foreign Proceedings: English High Court and Court of Appeal decisions (2014, 2016, 2017); Australian Federal Court decision (2019)
• Judgment Length: 45 pages; 14,179 words
• Cases Cited (from provided metadata): [2019] SGHC 231; [2021] SGCA 14

Summary

In Merck Sharp & Dohme Corp v Merck KGaA ([2021] SGCA 14), the Court of Appeal addressed how the doctrines of issue estoppel and abuse of process should operate when the alleged estoppel arises from a foreign judgment rather than a prior domestic decision. The case arose out of a long-running dispute between two corporate branches of the “Merck” business concerning their rights to use the “Merck” name and related branding. The parties’ relationship was governed by a co-existence agreement entered into in the 1970s, and the dispute had already produced significant litigation in England.

The Court of Appeal emphasised that while issue estoppel, cause of action estoppel, and abuse of process are all designed to prevent parties from being “twice vexed” and to uphold the finality of litigation, the legal framework for transnational issue estoppel (issue estoppel based on a foreign decision) cannot be applied mechanically in the same way as domestic issue estoppel. The court held that the principles governing domestic issue estoppel, as articulated in The Royal Bank of Scotland NV v TT International Ltd ([2015] 5 SLR 1104) (“RBS”), require modification when the prior decision is foreign, because additional considerations arise—particularly those affecting Singapore’s international relations and comity.

Ultimately, the Court of Appeal’s decision recalibrated the approach to transnational issue estoppel and clarified the interaction between issue estoppel and abuse of process in circumstances involving inconsistent positions and prior foreign litigation. The judgment is therefore both doctrinally significant and practically important for litigators seeking to rely on foreign judgments to preclude re-litigation in Singapore.

What Were the Facts of This Case?

The parties trace their origins to a German family business that began in 1668 under the name “E Merck”. Over time, the business developed into separate and independent branches operating in Europe and North America. In the 1970s, the predecessors of the parties entered into a co-existence arrangement to regulate how the name “Merck” could be used across different jurisdictions. This arrangement was documented in two instruments: a “1970 Agreement” and a “1975 Letter”.

The 1970 Agreement allocated rights and restrictions by reference to geography. For example, it provided that in the United States and Canada, “E. Merck” would not interfere with the exclusive right of Merck & Co. to use the “Merck” trademark, and it required geographic identification to avoid confusion. In Germany, it similarly recognised exclusive rights for each branch in relation to the trademark “Merck”. In “all other countries”, the agreement recognised that “Merck Sharp & Dohme” as a trademark or name was not confusingly similar to trademarks or names used or owned by E Merck, and it required the parties to refrain from objection and from adopting confusingly similar marks.

Clause 7 (as later interpreted in England) became central to the dispute. The English courts treated the agreement as precluding the appellant from using “Merck” on its own as a firm name or company name in the “rest of the world” (defined as all countries other than those where specific arrangements had been made). In other words, the dispute was not merely about trademark use in a narrow sense; it was about the contractual allocation of naming rights across jurisdictions.

Before Singapore proceedings commenced, there were multiple English decisions. First, the High Court of England and Wales determined that the governing law of the 1970 Agreement and the 1975 Letter was German law (the “English Preliminary Decision”). Second, the High Court interpreted various clauses, including clause 7, and held that the agreement barred the appellant’s use of “Merck” alone in the relevant jurisdictions and that the appellant had breached the agreement (the “HCEW Decision”). Third, the English Court of Appeal affirmed the HCEW Decision (the “ECA Decision”). The appellant later relied on an Australian Federal Court decision in 2019 which declined to decide separately whether the English Court of Appeal decision gave rise to issue estoppel in respect of clause 7, noting that the substantive proceedings were settled by consent without admissions.

In Singapore, the respondent and Merck Pte Ltd commenced Suit 415 against the appellant and other defendants on 23 April 2018, alleging trade mark infringement, passing off, and breach of contract. Before the High Court judge, the respondent sought summary judgment for breach of the co-existence agreement. The appellant resisted, relying on defences including the doctrines of issue estoppel and abuse of process, particularly in light of the English decisions. The appeal to the Court of Appeal therefore required the court to consider whether and how the English decisions could preclude re-litigation in Singapore, and whether the appellant’s positions amounted to an abuse of process.

What Were the Key Legal Issues?

The principal legal issue concerned the proper application of issue estoppel when the alleged estoppel is founded on a foreign judgment. The Court of Appeal recognised that issue estoppel, cause of action estoppel, and abuse of process are all part of the court’s “armoury” to prevent repeated litigation and to protect finality. However, the court stressed that the rationales and the legal rules may differ depending on whether the prior decision is domestic or foreign.

Related to this was the question of how the Henderson v Henderson doctrine (which prevents parties from raising in later proceedings matters that could and should have been raised earlier) and the broader abuse of process principle should apply in a transnational context. The court also had to consider whether the appellant had taken inconsistent positions across jurisdictions and whether such conduct should bar the appellant from advancing arguments in Singapore.

Finally, the court had to address the interaction between issue estoppel and the effect of foreign judgments, including the extent to which Singapore should give preclusive effect to foreign determinations in the interests of comity and international relations. This required the court to consider whether the domestic framework for issue estoppel needed recalibration.

How Did the Court Analyse the Issues?

The Court of Appeal began by situating the doctrines within their underlying purposes. Issue estoppel, cause of action estoppel, and abuse of process all serve to prevent litigants from being “twice vexed” in respect of the same or sufficiently similar issues, while also promoting the public interest in finality. In domestic issue estoppel, the court explained, these rationales primarily animate the formulation of the legal rules: protecting defendants from unfair vexation and upholding finality.

When the prior decision is foreign, however, the court held that additional considerations come into play. The court described this as “transnational issue estoppel” and noted that applying domestic principles without modification could have implications for Singapore’s international relations. In particular, the court considered that Singapore’s approach to foreign judgments should reflect comity and the broader policy environment governing cross-border recognition and enforcement.

To develop the modified approach, the Court of Appeal referred to the domestic framework in RBS (which sets out principles for domestic issue estoppel). The court accepted that those principles provide a starting point, but it held that they cannot apply without some modification in the transnational setting. The court considered it “pertinent” to have regard to legislative developments, including the promulgation of the Choice of Court Agreements Act (Cap 39A, 2017 Rev Ed) (“CCAA”), the planned repeal of the Reciprocal Enforcement of Commonwealth Judgments Act (Cap 264, 1985 Rev Ed), and amendments to the Reciprocal Enforcement of Foreign Judgments Act (Cap 265, 2001 Rev Ed) (“REFJA”). The thrust of this analysis was that Singapore’s legal system is evolving to manage cross-border litigation in a structured way, and the doctrine of transnational issue estoppel should align with that evolution.

Although the extract does not reproduce the full step-by-step application to the facts, the court’s reasoning can be understood as follows. First, the court treated the English decisions as potentially capable of giving rise to issue estoppel, but it insisted that the domestic test must be adapted to account for the foreign nature of the prior judgment. Second, the court considered whether the relevant issues were actually and necessarily decided in the foreign proceedings, and whether the parties had a fair opportunity to litigate those issues. Third, the court addressed whether the application of estoppel would be consistent with the interests of justice and with Singapore’s policy of respecting foreign adjudications while not allowing unfairness or procedural unfairness to be smuggled in through preclusion.

In addition, the court addressed abuse of process, including the Henderson v Henderson doctrine and the concept of inconsistent positions. The court’s framing indicates that abuse of process is not merely a technical label; it is a discretionary and policy-driven doctrine aimed at preventing unfairness and discouraging tactical litigation behaviour. Where a party takes positions inconsistent with its earlier conduct or seeks to re-litigate matters that should have been resolved, the court may intervene to prevent misuse of the process. In a transnational setting, the court’s analysis would also consider whether the party’s conduct undermines the fairness of the proceedings or the finality of foreign adjudication.

Finally, the court’s approach reflects a balancing exercise. It does not treat foreign judgments as automatically preclusive, nor does it ignore them. Instead, it calibrates the weight to be given to foreign determinations by reference to the interests of justice, the finality rationale, and Singapore’s international comity considerations. This is the core doctrinal contribution of the decision.

What Was the Outcome?

The Court of Appeal’s decision in Merck Sharp & Dohme Corp v Merck KGaA confirmed that transnational issue estoppel requires a modified approach rather than a mechanical importation of domestic issue estoppel principles. The court’s recalibration of the legal rules and its guidance on how abuse of process doctrines interact with foreign judgments provide a clearer framework for litigants seeking to rely on foreign determinations to preclude re-litigation in Singapore.

Practically, the outcome means that parties cannot assume that an English (or other foreign) appellate decision will automatically bar re-litigation in Singapore. Conversely, a party seeking to avoid preclusion cannot rely on the mere fact that the prior decision is foreign; the court will examine the interests of justice, fairness, and the policy considerations relevant to Singapore’s cross-border litigation posture.

Why Does This Case Matter?

This case matters because it addresses a recurring problem in cross-border commercial litigation: when should Singapore courts treat foreign judgments as sufficiently final and determinative to prevent re-litigation? The Court of Appeal’s insistence on modifying domestic issue estoppel principles for transnational contexts provides important doctrinal guidance for both litigators and judges.

For practitioners, the decision is particularly relevant in disputes involving multi-jurisdictional brand, IP, and contractual arrangements—exactly the kind of factual matrix that often produces parallel litigation. The “Merck” dispute illustrates how parties may litigate the same underlying contractual meaning and scope in one forum and then attempt to re-run arguments elsewhere. The Court of Appeal’s approach helps lawyers assess whether a foreign decision can be deployed as a preclusive shield (issue estoppel) or as a basis for resisting re-litigation (abuse of process).

From a precedent perspective, the case builds on RBS while clarifying that the transnational setting is not identical to the domestic setting. It also signals that Singapore courts will consider legislative developments in the recognition and enforcement of foreign judgments when shaping common law doctrines. This alignment between doctrine and statutory policy enhances predictability and supports a coherent cross-border litigation framework.

Legislation Referenced

• Choice of Court Agreements Act (Cap 39A, 2017 Rev Ed) (“CCAA”)
• Reciprocal Enforcement of Commonwealth Judgments Act (Cap 264, 1985 Rev Ed) (slated repeal referenced)
• Reciprocal Enforcement of Foreign Judgments Act (Cap 265, 2001 Rev Ed) (“REFJA”) (amendments referenced)

Cases Cited

• The Royal Bank of Scotland NV (formerly known as ABN Amro Bank NV) and others v TT International Ltd (nTan Corporate Advisory Pte Ltd and others, other parties) and another appeal [2015] 5 SLR 1104 (“RBS”)
• Merck KGaA v Merck Sharp & Dohme Corp & Others [2014] EWHC 3867 (Ch) (English Preliminary Decision)
• Merck KGaA v Merck Sharp & Dohme Corp, Merck & Co Inc, Merck Sharp & Dohme Limited, Intervet UK Limited, Intervet International BV [2016] EWHC 49 (Pat) (HCEW Decision)
• Merck KGaA v Merck Sharp & Dohme Corp, Merck & Co, Inc, Merck Sharp & Dohme Ltd, Intervet UK Ltd, Invervet International BV [2017] EWCA Civ 1834 (ECA Decision)
• Merck KGaA v Merck Sharp & Dohme Corp, Merck & Co Inc, Merck Sharp & Dohme Limited, Intervet UK Limited, Intervet International BV [2020] EWHC 1273 (Ch) (subsequent decision noted as not relevant to the appeal issues)
• Merck KGaA v Merck Sharp Dohme Corp [2019] FCA 1084 (FCA Decision)
• [2019] SGHC 231 (High Court decision referenced in provided metadata)
• [2021] SGCA 14 (this Court of Appeal decision)

Source Documents

• Original Judgment (PDF) — Singapore Law Watch
• Archived Copy (PDF) — Litt Law CDN

This article analyses [2021] SGCA 14 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.